Wiki livre Netizenship - Contributions de l’utilisateur [fr]

Postcard from... Calabria

2014-12-13T19:48:54Z

BrianneKohlmeier : Page créée avec « img, .hide-comment-buttons #singleCommentHeader .formContainer >.title, .hide-comment-buttons #loginButtonContainer display: none; /* Expandable MPU fix */ #side .x300 ... »

Let me ask you this: Why are email scams so poorly worded

2014-12-13T19:26:37Z

img, .hide-comment-buttons #singleCommentHeader .formContainer >.title, .hide-comment-buttons #loginButtonContainer display: none; /* Expandable MPU fix */ #side .x300 overflow: visible!important; /* Collapsing Skyscraper fix */ .ad [http://Thesaurus.com/browse/div.skyscraper div.skyscraper] height:auto!important;padding:0px!important; .ad div#mpu.skyscraper height:600px!important; Let me ask you this: 'Why are email scams so poorly worded?' - Features - Gadgets and Tech - The Independent Tuesday 09 December 2014 Apps eBooks i Jobs Dating Shop News Video People Voices Sport Tech Life Fashion News Features Food + Drink News Reviews Features Recipes Health & Families Health News Features Healthy Living Health Insurance [http://Dictionary.reference.com/browse/History?s=ts History] Gadgets and Tech News Features Motoring Motoring News Features Road Tests Motorcycling Comment Dating Advice Crosswords Gaming Competitions Christmas Property Arts + Ents Travel Money IndyBest Student Offers Cameron & Climate Change Breastfeeding Homeless Veterans Campaign - Donate George Osborne Greece Michael Gove Life >Gadgets and Tech >Features Let me ask you this: 'Why are email scams so poorly worded?' Saturday 06 September 2014 Print Your friend's email address Your email address Note: We do not store your email address(es) but your IP address will be logged to prevent abuse of this feature. Please read our Legal Terms & Policies A A A Email Like everyone else, I, too, always assumed that it was because either they were idiots, or non-native English speakers. But I have very recently learnt that is not the case. Indeed, the real answer is one of the more astonishing (at least to me) things I've heard in quite some time. It turns out that the dead giveaways of 'spamese' are completely deliberate and carefully calibrated. Huh? Why? Because, the obvious giveaways are used as a 'pre-qualifier', to ensure with the least possible effort that the ONLY people who respond to the scammers' initial mass mailings (and therefore have to be brought along individually during the later stages) are the absolutely most gullible, ignorant, susceptible suckers they can find. Absolutely brilliant! All of this has been explained in a detailed research paper published by Microsoft. David S Rose Wired magazine published a purported interview with a former Nigerian scammer in 2002. He described an elaborate business. Regarding the use of language: "The letters are intended to resemble soap operas that are popular in Nigeria, Taiwo [the former scammer] said, but with language that evokes someone who is 'educated, upper-class, out of touch with the common people'. 'I was told to write like a classic novelist would,' Taiwo explained. 'Very old world, very thick sentences, you know?'." The use of awkward English predates the mass email of the internet. I received a typed Nigerian scam letter 20 years ago that was sent by airmail from Africa. All scams and 'confidence tricks' are intended to catch people off guard while being maximally credible. Their strategy is to play into people's superstitions of how the world works and provide specific details to intrigue the imagination. The awkward formal English, in particular, fits how a lot of people think an upper-class African might talk whose family dates from the colonial era. Paul King Most modern spam filters user Bayesian filters, a statistical technique that estimates the probability of a message being spam. Bayesian spam filters are 'trained', so if you come up with a unique way to misspell Viagra, you have a better chance of getting through the filter. Geir Freysson, CEO of Brandregard.com 'Why are email scams so poorly worded'? originally appeared on Quora: The best answer to any question. Ask a question, get a great answer. Learn from experts and get insider knowledge. You can follow Quora on Twitter, Facebook, and Google+. Should you loved this information along with you wish to be given more details regarding [http://vipedtabletsonline24-7.com buy viagra] kindly check out our web-site.

Mohamed Al Fayed hits back at odd man Felix Magath amid Fulham crisis

2014-12-13T19:07:07Z

img, .hide-comment-buttons #singleCommentHeader .formContainer >.title, .hide-comment-buttons #loginButtonContainer display: none; /* Expandable MPU fix */ #side .x300 overflow: visible!important; /* Collapsing Skyscraper fix */ .ad div.skyscraper height:auto!important;padding:0px!important; .ad div#mpu.skyscraper height:600px!important; Mohamed Al Fayed hits back at 'odd man' Felix Magath amid Fulham crisis - Football League - Football - The Independent Tuesday 09 December 2014 Apps eBooks i Jobs Dating Shop News Video People Voices Sport Football International News & Comment Premier League Football League European Scottish FA & League Cups Transfers Videos Fixtures Premier League table Transfers Cricket Tennis Rugby Union News & Comment International Club Rugby Rugby League Golf Motor Racing Racing Boxing US Sport NFL NBA MLB NHL MLS Others Cycling Sailing Snooker Wrestling General Newsletter Video Premier League Cricket Tennis Rugby Union Rugby League 6 Nations Motorsport Golf World Cup news Tech Life Property Arts + Ents Travel Money IndyBest Student Offers Cameron & Climate Change Breastfeeding Homeless Veterans Campaign - Donate George Osborne Greece Michael Gove Sport >Football >Football League Mohamed Al Fayed hits back at 'odd man' Felix Magath amid Fulham crisis The former Cottagers owner took exception after he was blames for the club's current problems Simon Rice Simon Rice Simon Rice is Online Sports Editor for The Independent More articles from this journalist Follow Simon Rice Friday 29 August 2014 Print Your friend's email address Your email address Note: We do not store your email address(es) but your IP address will be logged to prevent abuse of this feature. Please read our Legal Terms & Policies A A A Email Mohamed Al Fayed has labelled Felix Magath an "odd man" after the Fulham manager blamed him for the club's current problems. Magath appeared to lay the blame for the Cottagers' dreadful fall from grace on the club's former owner, saying he "had not spent money" and that he "sold the best players and brought in average players. You cannot go on doing that for a long time." Since Fayed sold the club to Shahid Khan last summer, the club have been relegated from the Premier League and endured a dreadful start in the Championship that has left them with zero points after four games. Read more: Felix 'the dictator' Magath has been brutal in rebuilding Fulham - Sam WallaceHowever, Al Fayed has described [https://Www.jamendo.com/en/search?qs=fq=license_cc:(-nc%20AND%20-nd)&q=suggestions suggestions] he is to blame as "absurd" and was keen to point the finger back at Magath and "absentee landlord" Khan. Writing in his column for the London Evening Standard on Friday, Al Fayed said: "What an odd man Felix Magath is. I am not talking about the way he jumps around in the technical area when things go wrong on the pitch and then appeals to the dugout as if the physio and team doctor had caused it. "No, what's strange is that after losing Fulham's first four games of the Championship season, he has got time to criticise me - someone he has never met - instead of devoting every waking second to putting right his own glaring mistakes. "There is nothing dishonourable about failure, if you face up to it. Mr Magath isn't the first foreign coach to find the English game hard. What is wrong, and frankly un-English, is to blame someone else instead of taking responsibility for your own actions. "I sold my beloved Fulham on July 13, 2013. If a week is a long time in politics, 13 months is a lifetime in football. Mr Magath was brought in to stave off relegation from the Premier League but instead presided over a meek surrender. "It broke my heart. After 16 years at the helm at Craven Cottage, to see my work destroyed in a season was a bitter experience. To be blamed for that failure, is absurd. "Fortunately, there are 25,000 people who know the truth. The Fulham fans. I am content to be judged by them." Fulham manager Felix Magath Al Fayed also insisted he spent money in the best interests of the club, who saw their best years under his ownership as they reached the final of the Europa League in 2010. "We played our part in making it the best and most entertaining league in the world. Fulham achieved their highest ever top-flight finish, seventh," he wrote. "We carried English prestige into the inaugural season of the Europa League, taking Atletico Madrid into extra-time in the final and within five minutes of a penalty shoot-out. "Mr Magath says I bought only average players? So who were the men playing that night in Germany? I'll tell you: titans of the game and every one a hero. "In football, you cannot be an absentee landlord, as I fear Shahid Khan is most of the time. I went on the pitch before games. I met the fans. I talked to the players. I encouraged them. Yes, they are paid a lot of money but they are still young men who need inspiration. People work for people, not anonymous boards of directors. I gave the players gold chocolate bars from Harrods. If they needed to try harder, I handed out blue peppermints and said they were Viagra. "Those players never let me down. "The personal touch is important. Managers need encouragement too. Every manager I chose tried to take Fulham forward. Two of them became England managers." He added: "When I was young, there was a cartoon character, Felix the Cat. Whatever happened to him - whether he was run over on the road to Dover or blown up with dynamite - he just kept on walking. "If Fulham's results do not improve, starting with Cardiff tomorrow, perhaps this particular Felix should follow that cat down the road to Dover and then just keep on walking." If you have any sort of inquiries relating to where and ways to use [http://vipedtabletsonline24-7.com buy viagra], you could call us at our website.

Utilisateur:BrianneKohlmeier

2014-12-13T18:47:48Z

BrianneKohlmeier :

Im addicted to my hobby Kart racing. Sounds boring? Not! I also to learn Vietnamese in my spare time. my homepage - [http://vipedtabletsonline24-7.com buy viagra]

Cut-price Viagra available on the NHS after price fall

2014-12-13T16:55:44Z

BrianneKohlmeier : Page créée avec « img, .hide-comment-buttons #singleCommentHeader .formContainer >.title, .hide-comment-buttons #loginButtonContainer display: none; /* Expandable MPU fix */ #side... »

img, .hide-comment-buttons #singleCommentHeader .formContainer >.title, .hide-comment-buttons #loginButtonContainer display: none; /* Expandable MPU fix */ #side .x300 overflow: visible!important; /* Collapsing Skyscraper fix */ .ad div.skyscraper height:auto!important;padding:0px!important; .ad div#mpu.skyscraper height:600px!important; Cut-price Viagra available on the NHS after price fall - UK - News - The Independent Tuesday 09 December 2014 Apps eBooks i Jobs Dating Shop News UK Home News UK Politics Scottish independence Crime Weird News World Europe Americas Middle East Asia Africa Australasia World Politics World History Novaya Gazeta (English) WW1 Moments Business Business News Business Comment Business Analysis & Features Sharewatch SME Market News Market Epic Market Heatmaps Market Screener Business Directory ES Business Connections Create a business profile People Science Environment Climate Change Green Living Nature Media Opinion TV & Radio Press Online Advertising Technology Education News Schools Further Higher Primary Tables 2011 Secondary Tables 2012 Training & Courses MBA & Executive Images Obituaries Diary [http://En.Wiktionary.org/wiki/Corrections Corrections] Newsletter [http://www.twitpic.com/tag/Appeals Appeals] Video People Voices Sport Tech Life Property Arts + Ents Travel Money IndyBest Student Offers Cameron & Climate Change Breastfeeding Homeless Veterans Campaign - Donate George Osborne Greece Michael Gove News >UK Cut-price Viagra available on the NHS after price fall Viagra pills cost the NHS as little as �1.45 for a pack of four after the product's patent ran out last year Zachary Davies Boren Sunday 24 August 2014 Print Your friend's email address Your email address Note: We do not store your email address(es) but your IP address will be logged to prevent abuse of this feature. Please read our Legal Terms & Policies A A A Email Viagra can now be prescribed on the NHS to all men suffering from impotence after the expiry of the pill�s patent last year led to the development of cheap generic versions of the drug. Before this month only those who suffered from impotence as a side effect of illness or had been assessed by a specialist could be prescribed Viagra, but now hundreds of thousands of impotent men across the country have become eligible to be given the pills on the NHS. Some doctors are happy with this new policy, claiming it could save potentially save relationships, but others are concerned that demand for the drug will increase GP�s already heavy workloads. Pfizer's Viagra pills had cost �21.27 for a pack of four, whereas the new generic impotence pills, containing the active ingredient sildenafil, are priced at just �1.45 for a pack of four; a price reduction of 93 per cent. In 2012, the NHS spent �88 million on impotence medication for 180,000 men in England, �43 million of which was used to purchase branded Viagra. It is estimated that demand will nearly double in the next three years under the new rules, with 330,000 men across the country expected to be using the NHS for erectile dysfunction pills by 2017. Half of all men between the ages of 40 and 70 suffer from varying degrees of erectile dysfunction, according to the NHS. If you have any type of concerns regarding where and ways to make use of [http://vipedtabletsonline24-7.com viagra price], you could call us at the web-site.

UPDATE 3-Pfizer leaves investors guessing on intentions for Astra

2014-12-13T14:38:17Z

BrianneKohlmeier : Page créée avec « Pfizer Inc, which in May abandoned its $118 billion bid for AstraZeneca Plc, on Tuesday left investors guessing whether it would renew its pursuit of its British rival, bu... »

Pfizer Inc, which in May abandoned its $118 billion bid for AstraZeneca Plc, on Tuesday left investors guessing whether it would renew its pursuit of its British rival, but said it was considering other deals. The largest U.S. drugmaker reported higher-than-expected second-quarter revenue, helped by growing demand for its cancer medicines. But overall sales fell on competition with newer rival drugs and cheaper generics, trends that have quickened Pfizer's efforts to buy companies and drugs that can fortify its medicine chest. Under UK takeover rules, AstraZeneca can attempt to re-engage with Pfizer in August, and Pfizer can make another run at AstraZeneca in November. Pfizer officials on [http://Data.Gov.uk/data/search?q=Tuesday Tuesday] gave no hints of whether they would do so, although Chief Executive Ian Read said Pfizer is not currently "doing any work on AstraZeneca" because of a six-month quiet period imposed by U.K. regulators. "I think it's best to remain silent," Read said on an investor conference call, citing the takeover rules. Pfizer officially gave up its six-month quest to buy AstraZeneca after its final bid was rejected on May 26. It had hoped to locate the combined company in Britain, which has lower taxes than the United States, a maneuver called tax inversion. Read said Pfizer was also looking at other potential deals and that taxes would be one of three major considerations. Other factors are whether a potential acquisition is undervalued, and whether cost savings from a deal would offset a premium price for shares of the target company. Read said Pfizer shareholders appreciated the company's limiting the final Astra offer to 55 pounds a share, rather than the minimum bid of 59 pounds that the British company had wanted. While 4 pounds might not seem a major chasm, Chief Financial Officer Frank D'Amelio quickly interjected in an interview, "Every pound was $2 billion." Pfizer shares have been flat this year due to declining revenue, while the drug sector as a whole has seen shares rise 11 percent. In the next four years, generic rivals will challenge well-known Pfizer products such as the Celebrex painkiller, Lyrica nerve pain treatment and anti-impotence drug [http://vipedtabletsonline24-7.com Viagra], putting pressure on Pfizer to acquire new products. JP Morgan analyst Chris Schott speculated Pfizer may seek other tax-inversion opportunities if it is unable to reach a friendly deal with AstraZeneca. In the meantime, Pfizer is developing new drugs, including a promising treatment for breast cancer called Palbociclib that could be approved next year. Pfizer's research chief, Mikael Dolsten, said new uses for its Prevnar vaccine against pneumococcal bacteria and Xeljanz arthritis treatment could also bolster Pfizer. New vaccines against staph aureus and c. difficile bacteria could prove to be hidden gems in the Pfizer pipeline, he added. Pfizer earned $2.91 billion, or 45 cents per share, in the second quarter. That compared with $14.1 billion, or $1.98 per share, a year earlier, when it received more than $10 billion in proceeds from the spinoff of its animal health business, creating Zoetis. Excluding special items, Pfizer earned 58 cents per share. Analysts on average expected 57 cents, according to Thomson Reuters I/B/E/S. Sales fell 2 percent to $12.77 billion but exceeded Wall Street expectations of $12.46 billion. Sales of oncology medicines rose 16 percent to $570 million, but generic medicines that Pfizer calls established products and sells in emerging markets had lower sales. Pfizer stuck to its prior earnings forecast of $2.20 to $2.30 per share for the full year. Merck & Co, the second-biggest U.S. drugmaker, also reported higher-than-expected quarterly results on Tuesday. Pfizer shares closed down 1.2 percent to $29.73. (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn and David Gregorio)

AstraZeneca raises sales outlook as rival drugs are hit by delays

2014-12-13T13:45:17Z

img, .hide-comment-buttons #singleCommentHeader .formContainer >.title, .hide-comment-buttons #loginButtonContainer display: none; /* Expandable MPU fix */ #side .x300 overflow: visible!important; /* Collapsing Skyscraper fix */ .ad div.skyscraper height:auto!important;padding:0px!important; .ad div#mpu.skyscraper height:600px!important; AstraZeneca raises sales outlook as rival drugs are hit by delays - Business News - Business - The Independent Tuesday 09 December 2014 Apps eBooks i Jobs Dating Shop News UK Home News UK Politics Scottish independence Crime Weird News World Europe Americas Middle East Asia Africa Australasia World Politics World History Novaya Gazeta (English) WW1 Moments Business Business News Business Comment Business Analysis & Features Sharewatch SME Market News Market Epic Market Heatmaps Market Screener Business Directory ES Business Connections Create a business profile People Science Environment Climate Change Green Living Nature Media Opinion TV & Radio Press Online Advertising Technology Education News Schools Further Higher Primary Tables 2011 Secondary Tables 2012 Training & Courses MBA & Executive Images Obituaries Diary Corrections Newsletter Appeals Video People Voices Sport Tech Life Property Arts + Ents Travel Money IndyBest Student Offers Cameron & Climate Change Breastfeeding Homeless Veterans Campaign - Donate George Osborne Greece Michael Gove News >Business >Business News AstraZeneca raises sales outlook as rival drugs are hit by delays Sales in the third quarter jumped 5% to $6.5 billion Lucy Tobin Lucy Tobin Senior News Feature Writer at the Evening Standard, with business focus. Author of Ausperity, Entrepreneur + Guide to Uni Life. More articles from this journalist Follow Lucy Tobin Thursday 06 November 2014 Print Your friend's email address Your email address Note: We do not store your email address(es) but your IP address will be logged to prevent abuse of this feature. Please read our Legal Terms & Policies A A A Email The single life suits drugs giant AstraZeneca. The British pharma company posted its second sales upgrade in four months after rejecting Pfizer�s �70 billion takeover [https://www.gov.uk/search?q=attempt attempt] this spring. The firm was boosted by delays hitting the production of generic alternatives to its blockbuster ulcer and heartburn treatment, Nexium, in the crucial US market. That helped sales in the third quarter rise 5 per cent to $6.5 billion (�4.06 billion), a third-consecutive quarter of revenue growth. Other top-sellers were heart drug Brilinta, which had a 78 per cent surge in sales, and its diabetes portfolio. AstraZeneca now expects 2014�s revenues - when stripping out the effects of currency movements - to be higher by "low single digits" than last year. Business news in pictures That�s an upgrade from an earlier forecast of no growth, and comes after an original prediction that sales would fall by low-to-mid single digits was boosted in July by an announcement that annual sales would be flat. But net profit fell to $254 million in the third quarter, from $1.25 billion a year earlier, as AstraZeneca poured nearly double the amount of money into research and development as it did in the same time in 2013. Video: The latest business news At the start of this year, the FTSE 100 drugmaker was languishing in intensive care as its biggest medicines fell off patent and a string of cancer drug hopes failed at trials, triggering a share-price plunge. Then, in May, Viagra-maker Pfizer began its prolonged and ultimately unsuccessful takeover attempt. In fighting off that bid, AstraZeneca chief executive Pascal Soriot promised a 75 per cent increase in revenues to $45 billion by 2023 - but there�s a long way to go: City analysts forecast this year�s figure will hit just $25.9 billion. Under UK takeover rules, Pfizer can mount a fresh bid for AstraZeneca from the end of this month. Today Soriot cheered his "rapid transformation" of the drugmaker, but its shares fell 124p to 4494.75p. Should you loved this short article and you want to receive more information concerning [http://vipedtabletsonline24-7.com viagra price] please visit our own site.

Utilisateur:BrianneKohlmeier

2014-12-13T13:20:36Z

BrianneKohlmeier : Page créée avec « Nothing to say about myself at all. I enjoy of finally being a member of netizen3.org. I really hope I am useful in some way here. My site; [http://vipedtable... »

Nothing to say about myself at all. I enjoy of finally being a member of netizen3.org. I really hope I am useful in some way here. My site; [http://vipedtabletsonline24-7.com viagra price]

Pfizer s need for deal looms larger with earnings report

2014-12-13T12:52:37Z

BrianneKohlmeier : Page créée avec « Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, revivi... »

Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline. The largest U.S. drugmaker, whose laboratories have not come up with any big-selling new medicines for a decade, is expected to report significantly lower second-quarter revenue. While many industry watchers expect Pfizer to re-engage with Britain's AstraZeneca in coming months, some say the U.S. drugmaker should consider targets more focused on biotechnology, a strategy that has paid off for Merck & Co and Bristol-Myers Squibb Co. Although Pfizer is conducting trials of promising products - including breast cancer drug palbociclib and [http://Browse.deviantart.com/?q=vaccines vaccines] against meningitis and staph aureus - it needs far more drugs to generate meaningful sales growth, said Ori Hershkovitz, analyst with the Tel Aviv-based Sphera Fund, which holds Pfizer shares. "Pfizer is in a very desperate spot, having seen most of its pipeline disappoint and facing multiple patent expirations," he said. "It needs growth; it needs to buy a pipeline." Pfizer on May 26 officially abandoned its six-month quest for AstraZeneca after its final $118 billion offer was spurned. Investors still see a rationale for the deal, which would allow Pfizer to enjoy lower corporate tax rates as a UK-based company and a promising pipeline of new cancer treatments. Under British takeover law, AstraZeneca could reach out to Pfizer in August and Pfizer could make renewed overtures to its smaller rival in November. "I definitely think Pfizer will come back for Astra at a somewhat higher bid," Hershkovitz said. But he recommended Pfizer consider smaller targets whose treatments might broaden its existing research priorities, such as Belgium's UCB SA and Switzerland's Actelion Ltd. UCB, which makes treatments for epilepsy, rheumatoid arthritis and Parkinson's disease, has annual sales of $5 billion, and a market value of $17 billion. Actelion sells lucrative drugs for orphan diseases, rare and often life-threatening conditions that command high prices. It has annual sales of $2 billion and a market capitalization of $15 billion. Leerink Swann analyst Jason Gerberry has said it might make sense for Pfizer to buy Dublin-based generic drugmaker Actavis, which itself just bought U.S. specialty drugmaker Forest Laboratories for $25 billion. Disappointment with Pfizer is reflected in its stock price, which has fallen 1.4 percent this year, against a 11 percent gain for the ARCA Pharmaceutical Index of large U.S. and European drugmakers. Over the past two years, its shares have risen 27 percent, versus a 44 percent jump for the drug sector. A fresh wave of patent expirations on Pfizer's top drugs is approaching. Its Celebrex painkiller faces generics in the United States late this year, while impotence treatment [http://vipedtabletsonline24-7.com Viagra] goes generic in 2017. The company's biggest product, Lyrica for nerve pain, loses U.S. patent protection by 2018. The three drugs have combined annual sales of almost $9 billion, and account for almost 20 percent of Pfizer's total revenue. Biotechs with drugs already on the market and which also have exciting technologies should be on Pfizer's wish list, said Navid Malik, analyst with London-based Cenkos Securities. He cited companies such as Celgene Inc and Vertex Pharmaceuticals Inc. Roger Pomerantz, who headed business development at Merck from 2010 until last summer, said the potential of Merck's immuno-oncology drugs - medicines which train the immune system to recognize cancer cells - was not recognized even within the company for several years after it acquired them. "It's who you have on the inside helping you understand the science" that counts, he said. (Reporting by Ransdell Pierson; Editing by Michele Gershberg and Lisa Shumaker) Tweet this Link this Share this Digg this Email Print Reprints Trending On Reuters Follow Reuters Facebook Twitter RSS YouTube Edition: U.S. Arabic Argentina Brazil Canada China France Germany India Italy Japan Latin America Mexico Russia Spain United Kingdom Back to top Reuters.com Business Markets World Politics Technology Opinion Money Pictures Videos Site Index More from Reuters Reuters News Agency Brand Attribution Guidelines Delivery Options Support & Contact Support Corrections Connect with Reuters Twitter Facebook LinkedIn RSS Podcast Newsletters Mobile About Privacy Policy Terms of Use Advertise With Us AdChoices Copyright Our Flagship financial information platform incorporating Reuters Insider An ultra-low latency infrastructure for electronic trading and data distribution A connected approach to governance, risk and compliance Our next generation legal research platform Our global tax workstation Thomsonreuters.com About Thomson Reuters Investor Relations Careers Contact Us Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests. NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Chinese businessman arrested for secretly adding Viagra to alcoholic drinks

2014-12-13T11:03:52Z

Viagra can permanently damage vision scientists claim

2014-12-13T08:53:00Z

BrianneKohlmeier : Page créée avec « img, .hide-comment-buttons #singleCommentHeader .[http://www.squidoo.com/search/results?q=formContainer formContainer] >.title, .hide-comment-buttons #loginButtonContainer... »

img, .hide-comment-buttons #singleCommentHeader .[http://www.squidoo.com/search/results?q=formContainer formContainer] >.title, .hide-comment-buttons #loginButtonContainer display: none; /* Expandable MPU fix */ #side .x300 overflow: visible!important; /* Collapsing Skyscraper fix */ .ad div.skyscraper height:auto!important;padding:0px!important; .ad div#mpu.skyscraper height:600px!important; Viagra can permanently damage vision, scientists claim - Health News - Health & Families - The Independent Tuesday 09 [http://imgur.com/hot?q=December December] 2014 Apps eBooks i Jobs Dating Shop News Video People Voices Sport Tech Life Fashion News Features Food + Drink News Reviews Features Recipes Health & Families Health News Features Healthy Living Health Insurance History Gadgets and Tech News Features Motoring Motoring News Features Road Tests Motorcycling Comment Dating Advice Crosswords Gaming Competitions Christmas Property Arts + Ents Travel Money IndyBest Student Offers Cameron & Climate Change Breastfeeding Homeless Veterans Campaign - Donate George Osborne Greece Michael Gove Life >Health & Families >Health News Viagra can permanently damage vision, scientists claim People with a specific gene are more prone to the problems Kashmira Gander Kashmira Gander Kashmira Gander writes for the Independent and Independent on Sunday More articles from this journalist Follow Kashmira Gander Thursday 02 October 2014 Print Your friend's email address Your email address Note: We do not store your email address(es) but your IP address will be logged to prevent abuse of this feature. Please read our Legal Terms & Policies A A A Email An ingredient in Viagra could cause blindness in both men with eye problems and those with seemingly normal vision, according to a new study. Sildenafil, the active ingredient in the erectile dysfunction medication, could permanently damage the vision of a man with a hereditary eye condition, but also those who have normal sight and carry one gene linked to the eye problem, Australian researchers said. Scientists claim that the drug could cause permanent damage to the eyes of people with retinitis pigmentosa - a rare inherited disease which causes the cells in the retina to gradually die. Suffers can find it difficult to see in dim light, lose their peripheral vision, and can sometimes go blind. Around one in 50 people carry the genes which can trigger the retinal cell death. Read more: Cut-price Viagra available on the NHS after price fall Chinese businessman arrested for secretly adding Viagra to drinksTo make their findings published in the journal �Experimental Eye Research�, researchers from the University of New South Wales, Australia, gave a dose of sildenafil to healthy mice and ones with a copy of the mutant gene. The scientists discovered that the healthy mice experienced problems with their eyes for around two days. Health news: in pictures But mice with the gene had eye problems for a fortnight, the Mail Online reported. The researchers also identified early signs of cell death in the mices' retinas, indicating that the drug may cause loss of vision in people who carry the gene for the disease but have normal vision. Dr Lisa Nivison-Smith, of the UNSW School of Optometry and Vision Science, said: "If cells actually die in the retina that would lead to blindness." She went on to explain that people who have normal vision, but carry a single copy of the mutant gene for retinitis pigmentosa, could be more susceptible to changes caused by sildenafil. On its website, the NHS stressed that the study was only conducted on mice and therefore not yet proven in humans, but added that people should stop taking sildenafil citrate and seek immediate medical advice if they suddenly develop eye or eyesight problems. Should you have any concerns concerning where by and the best way to utilize [http://vipedtabletsonline24-7.com viagra price], you possibly can email us in the web-page.